Modality
siRNA
MOA
FcRni
Target
CD38
Pathway
Neuroinflam
FabryRBADHD
Development Pipeline
Preclinical
~Feb 2018
→ ~May 2019
Phase 1
~Aug 2019
→ ~Nov 2020
Phase 2
~Feb 2021
→ ~May 2022
Phase 3
~Aug 2022
→ ~Nov 2023
NDA/BLA
Feb 2024
→ Nov 2027
NDA/BLACurrent
NCT06261980
102 pts·RB
2024-02→2027-11·Not yet recruiting
102 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-11-231.6y awayPh3 Readout· RB
Trial Timeline
Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
NDA/BLA
Not yet…
Catalysts
Ph3 Readout
2027-11-23 · 1.6y away
RB
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06261980 | NDA/BLA | RB | Not yet recr... | 102 | PASI75 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CD38 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| NVS-6360 | Novartis | Approved | CD38 | |
| ABB-2476 | AbbVie | Phase 1/2 | USP1 | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-1361 | Novo Nordisk | Phase 3 | CD38 | |
| Suracagene | GSK | Phase 3 | PRMT5 | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 |